In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

In this video, Joseph M. Runde, DO, attending physician in gastroenterology, hepatology and nutrition at Ann & Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatrics at ...

Researchers at New York City-based Mount Sinai Health System have identified distinct biological markers in patients with mild Crohn’s disease, potentially paving the way for more personalized and ...

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with mild Crohn’s disease, offering a potential pathway toward more personalized ...

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to ...

Expanded indication of incisionless Exablate Neuro platform offers new hope for 50,000+ patients HAIFA, Israel and MIAMI, July 8, 2025 /CNW/ -- Insightec, a global healthcare innovator dedicated to ...

Fatigue and exhaustion are hallmarks of Crohn's disease. Try these tips for more energy and better health overall.

Background: Ustekinumab is used off-label in pediatric Crohn’s disease refractory to anti-tumor necrosis factor. Data on optimal dosing, target trough levels, and potential benefit of therapeutic drug ...

Seahawks Round-Up: Seahawks Mailbag, Mike Macdonald's Fathers Battle With Kidney Disease, His Ask And More All the Seahawks news you might have missed from this week.

Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with moderate to severe Crohn's disease into remission, according to a new study ...